<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00249977</url>
  </required_header>
  <id_info>
    <org_study_id>0103C</org_study_id>
    <nct_id>NCT00249977</nct_id>
  </id_info>
  <brief_title>Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan</brief_title>
  <official_title>Phase I Study Of Capecitabine in Combination With Cisplatin and Irinotecan in Patients With Advanced Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To determine the safety and feasibility of administering Capecitabine with the&#xD;
           combination of Cisplatin and Irinotecan.&#xD;
&#xD;
        2. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the&#xD;
           combination of Cisplatin and Irinotecan.&#xD;
&#xD;
        3. To study the biologic effect of pyrimidine inhibition on DNA repair after camptothecin&#xD;
           therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE: Many studies have tested the combination of cisplatin and irinotecan. Side effects&#xD;
      have been well described. The two drugs are synergistic.&#xD;
&#xD;
      The standard of care for colon cancer is the combination of 5-FU, leucovorin and irinotecan&#xD;
      (Saltz regimen). Recently, oxaliplatin has been introduced for the treatment of colon cancer.&#xD;
      Combination of oxaliplatin with 5FU (Folfox4) have shown comparable activity to the Saltz&#xD;
      regimen. Furthermore, one author recently published on the triple combination of oxaliplatin,&#xD;
      5FU and irinotecan, with impressive clinical activity in colon cancer.&#xD;
&#xD;
      There is some evidence that 5FU impairs DNA repair. One of the putative resistance mechanism&#xD;
      to topoisomerase I inhibitors is increased DNA repair. We therefore hypothesize that&#xD;
      inhibition of DNA repair by capecitabine may increase the activity of the combination of&#xD;
      cisplatin and irinotecan.&#xD;
&#xD;
      This study is open to all patients with solid tumor who have failed a line of chemotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety/feasibility of Capecitabine with the combination of Cisplatin and Irinotecan. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the combination of Cisplatin and Irinotecan.</measure>
    <time_frame>Progressing disease or unacceptable toxicities</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the biologic effect of pyrimidine inhibition on DNA repair after camptothecin therapy.</measure>
    <time_frame>disease progression, unacceptable toxicities</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine in Combination with Cisplatin and Irinotecan</intervention_name>
    <description>Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).&#xD;
Capecitabine will be administered from day 1 to day 10 PO starting on course 2.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients, 18 years of age or older, with incurable advanced cancer for whom there&#xD;
             is no effective therapy are eligible.&#xD;
&#xD;
          -  Patients must have a life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Patients must have a Zubrod performance status of 0-2.&#xD;
&#xD;
          -  Patients must sign an informed consent.&#xD;
&#xD;
          -  Patients should have adequate bone marrow function defined by an absolute peripheral&#xD;
             granulocyte count of &gt; 1,500 or cells/mm3 and platelet count &gt;100,000/mm3 and absence&#xD;
             of a regular red blood cell transfusion requirement.&#xD;
&#xD;
          -  Patients should have adequate hepatic function with a total bilirubin &lt; 2 mg/dl and&#xD;
             SGOT or SGPT &lt; two times the upper limit of normal, and adequate renal function as&#xD;
             defined by a serum creatinine &lt; 1.5 x upper limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic brain metastases are excluded from this study.&#xD;
&#xD;
          -  Pregnant women or nursing mothers are not eligible for this trial. Patients of child&#xD;
             bearing potential must use adequate contraception.&#xD;
&#xD;
          -  Patients may receive no other concurrent chemotherapy or radiation therapy during this&#xD;
             trial.&#xD;
&#xD;
          -  Patients with severe medical problems such as uncontrolled diabetes mellitus or&#xD;
             cardiovascular disease or active infections are not eligible for this trial.&#xD;
&#xD;
          -  Patients whose cancer progressed while receiving 5-FU, cisplatin or irinotecan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire F Verschraegen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2005</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Claire Verschraegen, M.D.; Principal Investigator</name_title>
    <organization>University of New Mexio - CRTC</organization>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>solid tumors</keyword>
  <keyword>DNA repair</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

